Navigation Links
MiMedx Announces 2012 Results
Date:3/7/2013

business, and the expected quarterly revenue growth. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the direct sales force strategy will not continue to produce quarter-over-quarter sales growth, that the clinical study results will not be as positive as anticipated or will not enable the Company to capture additional market presence, that a new patent will not issue in the near term  or that the claims, if any, allowed will be substantially reduced, that competitors can "design around" the Company's patents; that the Company may not be successful in entering into new placenta recovery contracts, that the Company's existing and future placental recovery contracts will not be sufficient to meet the Company's demand for tissue,  that the reimbursement coverage in the Medicare and commercial sectors does not materialize or expands at a rate slower than anticipated, that VA and government business will not continue to increase, that quarterly revenue growth will be below expectations, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2011. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

 MIMEDX GROUP, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS Years Ended December 31,REVENUES:20122011Net sales$
27,053,773$
7,760,446OPERATING COSTS AND EXPENSES:Cost of products sold

5,188,3783,357,909Research and development expenses

'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. MiMedx Group to Present at the 6th Annual OneMedForum
2. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. CCS Medical Announces Agreement with LifeScan
4. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
5. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. DMH International Announces The Launch of TouchPACS
9. Psyche Systems Announces Availability of Toxicology LIS
10. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
11. DDS Lab Announces Strategic Alliance with United Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
(Date:11/21/2014)... -- Oxis International, Inc. (OXIS) (OXI.PA) announced today the resignation ... J. Cataldo as Chief Executive Officer, and Steven ... Ken Eaton resigned his positions as Chief Executive ... International, Inc. to pursue new opportunities. Mr. ... of Oxis International, Inc. Mr. Cataldo will continue to serve ...
(Date:11/18/2014)... 18, 2014  NxStage ® Medical Inc. ... of innovative dialysis products , today announced ... dialyzer for the in-center, hemodialysis market.  Streamline Express ... designed to reduce the amount of labor required ... of touch point contamination sites.  The dialyzer enables ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2
... with its Investor Day being held tomorrow in New York ... forward-looking earnings expectations for the fourth quarter of Fiscal Year ... for Fiscal Year 2013.  The Company reconfirmed ... and for all of Fiscal Year 2012, as issued in ...
... hospitals handed a resolute vote of confidence over ... enterprise clinical and financial system. Healthmark Regional Medical ... Kit Carson Memorial Hospital plan on leveraging the ... meeting the meaningful use requirements associated with the ...
Cached Medicine Technology:PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 2PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 3PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 4Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System 2Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System 3
(Date:11/22/2014)... November 22, 2014 Setria® Glutathione ... (TGA) approved it for use “as a therapeutically ... listed within the Therapeutic Goods (Listing) Notice 2014 ... Kyowa Hakko’s Setria® Glutathione will be exclusivity distributed ... that sources and imports fine chemicals to Australian ...
(Date:11/22/2014)... 22, 2014 In order to provide better ... of cocktail party dresses. The business knows that a suitable ... occasions. , Now, the party dresses supplier’s high ... off. As the leading company in fashion industry, LunaDress understands ... for every customer. So it always raises the professional level ...
(Date:11/22/2014)... November 22, 2014 A petition seeking ... http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and fibroid removal ... the end of October, Bernstein Liebhard LLP reports. ... as of November 21st, 2014. That represents an increase ... had signed on to the campaign.* , The campaign ...
(Date:11/22/2014)... November 22, 2014 The topic of ... of block retaining walls. The article states that, “While they ... several necessary steps that go into creating this powerful look.” ... a retaining wall is choosing which kind of block matches ... , B&D Rockeries says, “The two main options are concrete ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident ... providing clients with the option of leaving an online ... flexible, intuitive and easy to navigate website that has ... Google + allows clients to research the Hastings and ... informed decision when retaining an attorney. Those who have ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... Events, DUBLIN, Ohio, April 8, 2008 Cardinal Health,Inc. ... services that improve,the safety and productivity of health care, plans ... prior to the opening of trading,on the New York Stock ... call for May 1 at,8:30 a.m. EDT to discuss results ...
... impact on childhood anxieties changes during adolescence, study found , , ... drive common fears, and new study finds, but the impact ... almost 2,500 twins born in Sweden from 1985 to 1986. ... ages 8 to 9, ages 13 to 14, ages 16 ...
... new study finds no effect , , TUESDAY, April 8 ... prevent relapses in patients with Crohn,s disease, concluded two ... Journal of the American Medical Association . , ... Dr. Brian Feagan, professor of medicine and director of ...
... Women on the hormone more than doubled the risk for ... Women who took a common form of estrogen as ... risk for certain types of benign breast disease compared with ... condition -- benign proliferative breast disease -- is relatively common ...
... mushroom (Ganoderma lucidum; Lingzhi) and green tea have long held ... countries, for the general promotion of health and long life ... studies have confirmed that both enhance the bodys immune functions ... types of cancer. , Now a new study ...
... frequently used illicit drugs by women during their childbearing ... during pregnancy, either alone or in combination with other ... There is strong evidence that THC, the main psychoactive ... abuse results in intrauterine growth retardation and that infants ...
Cached Medicine News:Health News:Cardinal Health to Announce Third-Quarter Results on May 1 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 3Health News:Genes' Influence on Fears Changes Over Time 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 3Health News:Estrogen Supplements May Raise Odds of Benign Breast Disease 2Health News:Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma 2Health News:Marijuana increases alcohol toxicity in young rats 2
... The Arx Ceramic ... innovative, biocompatible implants based ... technology that offers physicians ... to other synthetic and ...
CVC 9005 Hematocrit Calibration Verification Controls are materials used for verifying the calibration and linearity of hematocrit sensors in IRMA TRUpoint cartridges for systems using software versi...
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint®. CC 527 is available in ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
Medicine Products: